Brief: Allovir Reports Blinded Preliminary Phase 2 Data Supporting The Ongoing Study Of Posoleucel

Kalaris Therapeutics

07/06/2022 13:32

June 7 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR REPORTS BLINDED, PRELIMINARY, PHASE 2 DATA
SUPPORTING
THE ONGOING STUDY OF POSOLEUCEL, A MULTI-VIRUS-SPECIFIC T CELL
THERAPY, FOR THE TREATMENT OF BK VIREMIA IN KIDNEY TRANSPLANT
RECIPIENTS
    * ALLOVIR INC - PHASE 2 STUDY COMPLETED ENROLLMENT AHEAD OF
SCHEDULE
    * ALLOVIR INC - POSOLEUCEL WELL-TOLERATED WITH NO CASES OF
GRAFT
REJECTION OBSERVED TO DATE
    * ALLOVIR INC - OVERALL DECLINE IN MEDIAN BK VIRAL LOAD
AMONG
PATIENTS COMPLETING 12 WEEKS OF DOSING WITH POSOLEUCEL OR
PLACEBO
    * ALLOVIR INC - POSOLEUCEL DETECTED UP TO 12 WEEKS AFTER
LAST
INFUSION
    * ALLOVIR INC - TOPLINE, UNBLINDED STUDY RESULTS FROM ALL 61
PATIENTS EXPECTED TO BE RELEASED IN 1Q 2023

Source text for Eikon:  ID:nBw31d1Ja 
Further company coverage:  ALVR.O 

 ((reuters.briefs@thomsonreuters.com;))